<DOC>
	<DOC>NCT02641392</DOC>
	<brief_summary>This is a Phase 3, double-blind, active treatment extension study to evaluate the long-term safety of GED-0301 over 208 weeks in subjects with Crohn's disease (CD) who previously participated in either of the following two Phase 3 GED-0301 studies: - Study GED-0301-CD-002 - Study GED-0301-CD-003</brief_summary>
	<brief_title>A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease</brief_title>
	<detailed_description>This is a long-term active treatment study in patients with Crohn's disease (CD). Subjects who met the early escape criteria in Study GED-0301-CD-002, or subjects who completed Study GED-0301-002 or GED-0301-003, may be eligible for this study. The duration of the treatment is up to 208 weeks and will consist of 3 periods: - Screening Period - up to 4 weeks - Long-term Active Treatment Period - 208 Weeks (Week 0 to Week 208) - Follow-up Period - 4 weeks (ie, no Investigational product (IP) taken) The primary objective is to assess long-term safety of GED 0301. Additional efficacy and patient reported outcomes will be explored.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must satisfy the following criteria to be screened and enrolled in the study: Male or female ≥ 18 years of age. Subject must have participated in the GED0301CD002 or GED 0301 CD 003 study. Subject must use protocol approved contraception. The presence of any of the following will exclude a subject from screening and enrollment: Subject had experienced a serious adverse event (SAE) related to the investigational product while participating in the previous Phase 3 GED0301 study. Subject has initiated biologic agents, such as TNFα blockers or integrin antagonists. Subject is pregnant or breastfeeding. Subject has developed a known hypersensitivity to oligonucleotides, GED 0301 or any ingredient in the investigational product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>GED 0301</keyword>
	<keyword>Mongersen</keyword>
	<keyword>Safety</keyword>
	<keyword>IBD</keyword>
</DOC>